Drug Profile
ELND 002
Alternative Names: ELND-002Latest Information Update: 18 Jan 2012
Price :
$50
*
At a glance
- Originator Elan Corporation
- Class Small molecules
- Mechanism of Action Integrin alpha4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological malignancies; Multiple sclerosis
Most Recent Events
- 03 Jan 2012 Elan Pharmaceuticals completes enrolment in its phase Ib trial for Multiple sclerosis in USA & Canada (NCT01144351)
- 30 Dec 2011 Discontinued - Phase-I for Multiple sclerosis in Canada (SC)
- 30 Dec 2011 Discontinued - Phase-I for Multiple sclerosis in USA (SC)